Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
16th October 2020 | David Sidransky | 16,667 | Exercise of derivative | $5.46 | $91,001.82 |
16th October 2020 | David Sidransky | 10,100 | Payment by withholding | $9.01 | $91,001.00 |
20th May 2020 | David Sidransky | 10 | Open or private purchase | $6.98 | $69.80 |
13th May 2020 | David Sidransky | 70 | Open or private purchase | $5.96 | $417.20 |
12th May 2020 | David Sidransky | 90 | Open or private purchase | $5.90 | $531.00 |
7th May 2020 | David Sidransky | 10 | Open or private purchase | $5.42 | $54.20 |
11th June 2018 | Yaron Adler | 37,662 | Conversion of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Orgenesis, Inc. engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.